Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1179-1918

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience? ; day:2 ; month:3 ; year:2018 ; pages:1-10
Clinical drug investigation ; (2.3.2018), 1-10

Creator: Goldsmith, David

Contributor: Dellanna, Frank
Schiestl, Martin
Krendyukov, Andriy
Combe, Christian
SpringerLink (Online service)

DOI: 10.1007/s40261-018-0637-1

URN: urn:nbn:de:1111-201805092647

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:51 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Goldsmith, David
Dellanna, Frank
Schiestl, Martin
Krendyukov, Andriy
Combe, Christian
SpringerLink (Online service)

Other Objects (12)

Biosimilars – Biosimilars: ja, aber

Biosimilars

A Decade of Imaging Patients with Traumatic Brachial Plexopathy: What have we Learned?

Biosimilars : Handbuch

Biosimilars : ein Handbuch

Biosimilars – Alternative wirkt

GOAL: What Have We Learned?

Turning genes into medicines—what have we learned from gene therapy drug development in the past decade?

Biosimilars im Fokus : Diskussionspapier zur Substitution von Biosimilars in Apotheken

Zika Virus: What Have We Learned?

Current perspectives on biosimilars

What have we learned from a decade of patient involvement in OMERACT and its effect on trial outcome assessments?

Biosimilars – Biosimilars: ja, aber

Biosimilars

A Decade of Imaging Patients with Traumatic Brachial Plexopathy: What have we Learned?

Biosimilars : Handbuch

Biosimilars : ein Handbuch

Biosimilars – Alternative wirkt

GOAL: What Have We Learned?

Turning genes into medicines—what have we learned from gene therapy drug development in the past decade?

Biosimilars im Fokus : Diskussionspapier zur Substitution von Biosimilars in Apotheken

Zika Virus: What Have We Learned?

Current perspectives on biosimilars

What have we learned from a decade of patient involvement in OMERACT and its effect on trial outcome assessments?

Biosimilars – Biosimilars: ja, aber

Biosimilars

A Decade of Imaging Patients with Traumatic Brachial Plexopathy: What have we Learned?

Biosimilars : Handbuch

Biosimilars : ein Handbuch

Biosimilars – Alternative wirkt

GOAL: What Have We Learned?

Turning genes into medicines—what have we learned from gene therapy drug development in the past decade?

Biosimilars im Fokus : Diskussionspapier zur Substitution von Biosimilars in Apotheken

Zika Virus: What Have We Learned?

Current perspectives on biosimilars

What have we learned from a decade of patient involvement in OMERACT and its effect on trial outcome assessments?

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Biosimilars – Biosimilars: ja, aber

Biosimilars

A Decade of Imaging Patients with Traumatic Brachial Plexopathy: What have we Learned?

Biosimilars : Handbuch

Biosimilars : ein Handbuch

Biosimilars – Alternative wirkt

GOAL: What Have We Learned?

Turning genes into medicines—what have we learned from gene therapy drug development in the past decade?

Biosimilars im Fokus : Diskussionspapier zur Substitution von Biosimilars in Apotheken

Zika Virus: What Have We Learned?

Current perspectives on biosimilars

What have we learned from a decade of patient involvement in OMERACT and its effect on trial outcome assessments?

Biosimilars – Biosimilars: ja, aber

Biosimilars

A Decade of Imaging Patients with Traumatic Brachial Plexopathy: What have we Learned?

Biosimilars : Handbuch

Biosimilars : ein Handbuch

Biosimilars – Alternative wirkt

GOAL: What Have We Learned?

Turning genes into medicines—what have we learned from gene therapy drug development in the past decade?

Biosimilars im Fokus : Diskussionspapier zur Substitution von Biosimilars in Apotheken

Zika Virus: What Have We Learned?

Current perspectives on biosimilars

What have we learned from a decade of patient involvement in OMERACT and its effect on trial outcome assessments?

Biosimilars – Biosimilars: ja, aber

Biosimilars

A Decade of Imaging Patients with Traumatic Brachial Plexopathy: What have we Learned?

Biosimilars : Handbuch

Biosimilars : ein Handbuch

Biosimilars – Alternative wirkt

GOAL: What Have We Learned?

Turning genes into medicines—what have we learned from gene therapy drug development in the past decade?

Biosimilars im Fokus : Diskussionspapier zur Substitution von Biosimilars in Apotheken

Zika Virus: What Have We Learned?

Current perspectives on biosimilars

What have we learned from a decade of patient involvement in OMERACT and its effect on trial outcome assessments?

Related objects

Reset password